jk CG, Stehouwer CD, Ebeling P, et al. Soluble vascular cell adhesion molecule-1 and soluble E-selectin are associated with micro- and macrovascular complications in Type 1 BS-181 biological activity diabetic patients. J Diabetes Complications 20: 18895. 15. Barile GR, Chang SS, Park LS, Reppucci VS, Schiff WM, et al. Soluble cellular adhesion molecules in proliferative vitreoretinopathy and proliferative diabetic retinopathy. Curr Eye Res 19: 21927. 16. Limb GA, Hickman-Casey J, Hollifield RD, Chignell AH Vascular adhesion molecules in vitreous from eyes with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 40: 2453457. 17. Hatchell DL, Wilson CA, Saloupis P Neutrophils plug capillaries in acute experimental retinal ischemia. Microvasc Res 47: 34454. 18. Adamiec-Mroczek J, Oficjalska-Mlynczak J Assessment of selected adhesion molecule and proinflammatory cytokine levels in the vitreous body of patients with type 2 diabetes–role of the inflammatory-immune process in the pathogenesis of proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 246: 1665670. 19. Matsumoto K, Sera Y, Ueki Y, Inukai G, Niiro E, et al. Comparison of serum concentrations of soluble adhesion molecules in diabetic microangiopathy 
and macroangiopathy. Diabet Med 19: 82226. 20. Nowak M, Wielkoszynski T, Marek B, Kos-Kudla B, Swietochowska E, et al. Blood serum levels of vascular cell adhesion molecule, intercellular adhesion molecule and endothelial leucocyte adhesion molecule-1 in diabetic retinopathy. Clin Exp Med 8: 15964. 21. Galkina E, Ley K Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol 27: 16597. 22. Leiter LA The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering Diabetes Res Clin Pract 68 Suppl 2: S34. 23. Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes 46: 1829839. 24. Lyons TJ, Jenkins AJ, Zheng D, Lackland DT, McGee D, et al. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci 45: 91018. 25. Dodson PM Management of diabetic retinopathy: could lipid-lowering be a worthwhile treatment modality Eye 23: 997003. 26. Keech AC, 25331948 Mitchell P, Summanen PA, O’Day J, Davis TM, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy: a randomised controlled trial. Lancet 370: 1687697. 27. The ASGaAESG Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes. N Engl J Med: NEJMoa1001288. 28. Boyles JK, Pitas RE, Wilson E, Mahley RW, Taylor JM Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest 76: 1501513. 29. Adamis AP, Berman AJ Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol 30: 654. 30. Bertazza L, Mocellin S Tumor necrosis factor biology and cell death. Front Biosci 13: 2736743. 31. Chadwick W, Magnus T, Martin B, Keselman A, Mattson MP, et al. Targeting TNF-alpha receptors for neurotherapeutics. Trends Neurosci 31: 50411. 32. Kruglov AA, Kuchmiy A, Grivennikov SI, Tumanov AV, Kuprash DV, et al. Physiological functions of tumor necrosis factor and the consequences of its pathologic overexpression or blockade: mouse models. Cytokine Growth Factor Rev 19: 23144. 33. Wu KK, Huan Y Diabetic atherosclerosis mouse models. A